All In Biotech

Drug Trial Radar · NCT05441956

TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)

A Dose Escalation and Expansion Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-326 Monotherapy for the Treatment of Advanced ALK-positive or ROS1-positive Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

198

Actual

Start

Apr 23, 2021

Primary completion

Aug 31, 2025

Study completion Oct 31, 2025

Sponsor

Lead sponsor
Shenzhen TargetRx Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Sun Yat-Sen University Cancer Center
First posted
Jul 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a multi-center, single-arm, open-label, Phase I clinical trial in 3 phases: dose escalation phase, dose expansion phase and indication expansion phase, which will explore the safety, tolerability, PK and preliminary efficacy of TGRX-326 in patients with ALK-positive or ROS1-positive advanced NSCLC.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • TGRX-326Drug

    Participants are given TGRX-326 tablets orally at one of the dose levels as pre-determined.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximal tolerated dose (MTD)Time frame: At end of Cycle 1 (each cycle is 21 days) when the probability of DLT of a dose level is higher than 33%
  2. Recommended phase II dose (RP2D)Time frame: At completion of the dose expansion study, an average of 1 year
  3. Safety profile (DLT)Time frame: Collect during Cycle 1 (each cycle is 21 days)
  4. Safety profile (AEs/SAEs)Time frame: Through completion of the study, an average of 1.5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.